Biogen Shortens Its Name, Expands Focus On Alzheimer’s Treatments

Biogen Shortens Its Name, Expands Focus On Alzheimer’s Treatments
biogen nlThanks to its successful drugs to address treatments for multiple sclerosis, Biogen Idec Inc has seen its position in the biopharmaceutical market increase, having quadrupled sales in just 3 years to over $100 billion dollars. The company now has new ambitions in sight and has dropped "Idec" from its name and adopted a new logo to indicate its new focus, which will include drug development efforts for Alzheimer's disease. The Massachusetts-based company recently announced better-than-expected outcomes of its clinical trial concerning aducanumab, an Alzheimer's drug. The results are spurring on a new initiative for the company to address the significant unmet medical needs in the Alzheimer's patient community. George Scangos, Chief Executive, stated that Biogen will remain focused on developing drugs to address some of the most difficult diseases to treat. "Five years down the road, with some luck, we'll have an Alzheimer's drug that's getting approved. I hope we can transform the treatment of MS. By that time, we will have made substantial progress on ALS and other nerve degenerative diseases, spinal muscular atrophy in kids. All that stuff is on our plate," said Scangos in the
Subscribe or to access all post and page content.